Ahmed N Mahmoud1, Mohamed M Gad2, Akram Y Elgendy1, Islam Y Elgendy1, Anthony A Bavry1,3. 1. Division of Cardiovascular Medicine, Department of Medicine, University of Florida, 1600 SW Archer Road, Gainesville, FL, USA. 2. Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH, USA. 3. North Florida/South Georgia Veterans Health System, Malcom Randall Veterans Administration Medical Center, Medical Service, Cardiology Section (111D), 1601 SW Archer Road, Gainesville, FL, USA.
Abstract
AIMS: The role of aspirin in the primary prevention setting is continuously evolving. Recent randomized trials have challenged the role of aspirin in the primary prevention setting. METHODS AND RESULTS: Electronic databases were searched for randomized trials that compared aspirin vs. placebo (or control) in subjects without established atherosclerotic disease. The primary efficacy outcome was all-cause mortality, while the primary safety outcome was major bleeding. Summary estimates were reported using a DerSimonian and Laird random effects model. A total of 11 trials with 157 248 subjects were included. At a mean follow-up of 6.6 years, aspirin was not associated with a lower incidence of all-cause mortality [risk ratio (RR) 0.98, 95% confidence interval (CI) 0.93-1.02; P = 0.30]; however, aspirin was associated with an increased incidence of major bleeding (RR 1.47, 95% CI 1.31-1.65; P < 0.0001) and intracranial haemorrhage (RR 1.33, 95% CI 1.13-1.58; P = 0.001). A similar effect on all-cause mortality and major bleeding was demonstrated in diabetic and high cardiovascular risk patients (i.e. 10-year risk >7.5%). Aspirin was associated with a lower incidence of myocardial infarction (RR 0.82, 95% CI 0.71-0.94; P = 0.006); however, this outcome was characterized by considerable heterogeneity (I2 = 67%), and this effect was no longer evident upon limiting the analysis to the more recent trials. Trial sequential analysis confirmed the lack of benefit of aspirin for all-cause mortality up to a relative risk reduction of 5%. CONCLUSION: Among adults without established cardiovascular disease, aspirin was not associated with a reduction in the incidence of all-cause mortality; however, it was associated with an increased incidence of major bleeding. The routine use of aspirin for primary prevention needs to be reconsidered. Published by Oxford University Press on behalf of the European Society of Cardiology 2018.
AIMS: The role of aspirin in the primary prevention setting is continuously evolving. Recent randomized trials have challenged the role of aspirin in the primary prevention setting. METHODS AND RESULTS: Electronic databases were searched for randomized trials that compared aspirin vs. placebo (or control) in subjects without established atherosclerotic disease. The primary efficacy outcome was all-cause mortality, while the primary safety outcome was major bleeding. Summary estimates were reported using a DerSimonian and Laird random effects model. A total of 11 trials with 157 248 subjects were included. At a mean follow-up of 6.6 years, aspirin was not associated with a lower incidence of all-cause mortality [risk ratio (RR) 0.98, 95% confidence interval (CI) 0.93-1.02; P = 0.30]; however, aspirin was associated with an increased incidence of major bleeding (RR 1.47, 95% CI 1.31-1.65; P < 0.0001) and intracranial haemorrhage (RR 1.33, 95% CI 1.13-1.58; P = 0.001). A similar effect on all-cause mortality and major bleeding was demonstrated in diabetic and high cardiovascular risk patients (i.e. 10-year risk >7.5%). Aspirin was associated with a lower incidence of myocardial infarction (RR 0.82, 95% CI 0.71-0.94; P = 0.006); however, this outcome was characterized by considerable heterogeneity (I2 = 67%), and this effect was no longer evident upon limiting the analysis to the more recent trials. Trial sequential analysis confirmed the lack of benefit of aspirin for all-cause mortality up to a relative risk reduction of 5%. CONCLUSION: Among adults without established cardiovascular disease, aspirin was not associated with a reduction in the incidence of all-cause mortality; however, it was associated with an increased incidence of major bleeding. The routine use of aspirin for primary prevention needs to be reconsidered. Published by Oxford University Press on behalf of the European Society of Cardiology 2018.
Authors: Theodore Wein; M Patrice Lindsay; David J Gladstone; Alexandre Poppe; Alan Bell; Leanne K Casaubon; Norine Foley; Shelagh B Coutts; Jafna Cox; James Douketis; Thalia Field; Laura Gioia; Jeffrey Habert; Eddy Lang; Shamir R Mehta; Christine Papoushek; William Semchuk; Mikul Sharma; Jacob A Udell; Stephanie Lawrence; Anita Mountain; Gord Gubitz; Dar Dowlatshahi; Anne Simard; Andrea de Jong; Eric E Smith Journal: CMAJ Date: 2020-10-05 Impact factor: 8.262
Authors: Samuel Cykert; Thomas C Keyserling; Michael Pignone; Darren DeWalt; Bryan J Weiner; Justin G Trogdon; Thomas Wroth; Jacqueline Halladay; Monique Mackey; Jason Fine; Jung In Kim; Crystal Cene Journal: Health Serv Res Date: 2020-10-13 Impact factor: 3.402
Authors: Theodore Wein; M Patrice Lindsay; David J Gladstone; Alexandre Poppe; Alan Bell; Leanne K Casaubon; Norine Foley; Shelagh B Coutts; Jafna Cox; James Douketis; Thalia Field; Laura Gioia; Jeffrey Habert; Eddy Lang; Shamir R Mehta; Christine Papoushek; William Semchuk; Mikul Sharma; Jacob A Udell; Stephanie Lawrence; Anita Mountain; Gord Gubitz; Dar Dowlatshahi; Anne Simard; Andrea de Jong; Eric E Smith Journal: CMAJ Date: 2020-03-23 Impact factor: 8.262
Authors: Davide Capodanno; Deepak L Bhatt; John W Eikelboom; Keith A A Fox; Tobias Geisler; C Michael Gibson; Jose Ramon Gonzalez-Juanatey; Stefan James; Renato D Lopes; Roxana Mehran; Gilles Montalescot; Manesh Patel; P Gabriel Steg; Robert F Storey; Pascal Vranckx; Jeffrey I Weitz; Robert Welsh; Uwe Zeymer; Dominick J Angiolillo Journal: Nat Rev Cardiol Date: 2020-01-17 Impact factor: 32.419